[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100475707":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":28,"responsibleParty":45,"collaborators":49,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Iowa","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cystic Fibrosis Carrier Group",null,"Participants have been identified as Cystic Fibrosis Carriers via previous genetic testing.",{"label":13,"type":10,"description":14,"interventionNames":10},"Control Group","Participants have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.",[16],{"name":17,"affiliation":5,"role":18},"Philip M Polgreen, MD","PRINCIPAL_INVESTIGATOR",[20,24],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","(319) 384-6194","philip-polgreen@uiowa.edu",{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},"Shelby L Francis, PhD","319-678-8037","shelby-francis@uiowa.edu",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"University of Iowa Hospitals and Clinics","RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-91.53017,41.66113,{"lat":41,"lon":40},[44],{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Philip Polgreen","Professor, Internal Medicine",[50,53],{"name":51,"class":52},"National Institutes of Health (NIH)","NIH",{"name":54,"class":52},"National Institute of Allergy and Infectious Diseases (NIAID)","100475707","estimating-risk-of-respiratory-infections-attributable-to-cftr-heterozygosity-100475707",false,"NCT05474430","Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity","Estimating the Risk for and Severity of Respiratory Infections Attributable to CFTR Heterozygosity","CF Carrier Inclusion Criteria:\n\n* Previously tested and shown to be a CF carrier\n* English-speaking\n\nControl Group Inclusion Criteria:\n\n* Previously tested and shown to not be a CF carrier or CF patient\n* English-speaking\n\nExclusion Criteria:\n\n* Currently sick with a respiratory infection\n* Prisoner Status\n* Unable to provide own written, informed consent","ALL","18 Years","100 Years",{"count":66,"type":67},160,"ESTIMATED","OBSERVATIONAL","A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays.\n\nAn individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19.\n\nThe participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.",[71,72],"Carrier State","Respiratory Infections","2026-01-05",{"date":75,"type":76},"2026-01-07","ACTUAL",{"date":78,"type":76},"2021-12-20",{"date":80,"type":67},"2026-07",{"name":47,"class":6},1]